Sigma-Tau S.p.A. – Product Pipeline Review – Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “Sigma-Tau S.p.A. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Sigma-Tau S.p.A. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Sigma-Tau S.p.A. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sigma-Tau S.p.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sigma-Tau S.p.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sigma-Tau S.p.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Sigma-Tau S.p.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sigma-Tau S.p.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sigma-Tau S.p.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sigma-Tau S.p.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sigma-Tau S.p.A. and identify potential opportunities in those areas.
Table of Content
Table of Content
List of Tables
List of Figures
Sigma-Tau S.p.A. Snapshot
Sigma-Tau S.p.A. Overview
Key Information
Key Facts
Sigma-Tau S.p.A. – Research and Development Overview
Key Therapeutic Areas
Sigma-Tau S.p.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Sigma-Tau S.p.A. – Pipeline Products Glance
Sigma-Tau S.p.A. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Sigma-Tau S.p.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sigma-Tau S.p.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Sigma-Tau S.p.A. – Drug Profiles
Chenorm
Product Description
Mechanism of Action
R&D Progress
Cystoran
Product Description
Mechanism of Action
R&D Progress
Nuartez
Product Description
Mechanism of Action
R&D Progress
Acetyl-L-Carnitine
Product Description
Mechanism of Action
R&D Progress
Defibrotide
Product Description
Mechanism of Action
R&D Progress
Statins/Omega-3 PUFA
Product Description
Mechanism of Action
R&D Progress
Acetyl-L-Carnitine
Product Description
Mechanism of Action
R&D Progress
Dacarbazine + Interferon Apha + Thymosin-Alpha-1
Product Description
Mechanism of Action
R&D Progress
Dacarbazine + Thymosin-Alpha-1
Product Description
Mechanism of Action
R&D Progress
Gimatecan
Product Description
Mechanism of Action
R&D Progress
IART
Product Description
Mechanism of Action
R&D Progress
Rostafuroxin
Product Description
Mechanism of Action
R&D Progress
Teglicar
Product Description
Mechanism of Action
R&D Progress
Adarotene
Product Description
Mechanism of Action
R&D Progress
Namitecan
Product Description
Mechanism of Action
R&D Progress
ST1535
Product Description
Mechanism of Action
R&D Progress
STP-206
Product Description
Mechanism of Action
R&D Progress
DN30
Product Description
Mechanism of Action
R&D Progress
PTX3
Product Description
Mechanism of Action
R&D Progress
SST0001
Product Description
Mechanism of Action
R&D Progress
ST1936
Product Description
Mechanism of Action
R&D Progress
HSP90 inhibitors
Product Description
Mechanism of Action
R&D Progress
Sigma-Tau S.p.A. – Pipeline Analysis
Sigma-Tau S.p.A. – Pipeline Products by Therapeutic Class
Sigma-Tau S.p.A. - Pipeline Products By Target
Sigma-Tau S.p.A. – Pipeline Products by Route of Administration
Sigma-Tau S.p.A. – Pipeline Products by Molecule Type
Sigma-Tau S.p.A. – Recent Pipeline Updates
Sigma-Tau S.p.A. – Company Statement
Sigma-Tau S.p.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Sigma-Tau S.p.A., Deals Volume Summary, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary By Region, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary, 2004 to YTD 2011
Sigma-Tau S.p.A. Detailed Deal Summary
Equity Offering
RegeneRx Biopharmaceuticals Completes Private Placement Of $1 Million
RegeneRx Completes Private Placement Of $9.55 Million
Endotis Enters Into Manufacturing And Co-Development Agreement With Tecnogen
Anesiva Expands Its Agreement With Sigma-Tau
Anesiva Entered Into Agreement With Sigma-Tau
Recordati Signs Co-Marketing Agreement With Sigma-Tau
BurnsAdler Pharmaceuticals Enters Into Co-Promotion Agreement With Sigma-Tau
Licensing Agreements
Pfizer Enters Into Licensing Agreement With Sigma-Tau
Debiopharm Enters Into Licensing Agreement with Sigma-Tau
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Sigma-Tau S.p.A. – Pipeline by Therapy Area and Indication, 2011
Sigma-Tau S.p.A. – Pipeline by Stage of Development, 2011
Sigma-Tau S.p.A. – Monotherapy Products in Pipeline, 2011
Sigma-Tau S.p.A. – Combination Treatment Modalities in Pipeline, 2011
Sigma-Tau S.p.A. – Filed, 2011
Sigma-Tau S.p.A. – Phase III, 2011
Sigma-Tau S.p.A. - Phase II, 2011
Sigma-Tau S.p.A. - Phase I, 2011
Sigma-Tau S.p.A. - Pipeline By Therapeutic Class, 2011
Sigma-Tau S.p.A. - Pipeline By Target, 2011
Sigma-Tau S.p.A. – Pipeline By Route of Administration, 2011
Sigma-Tau S.p.A. – Pipeline By Molecule Type, 2011
Sigma-Tau S.p.A. – Recent Pipeline Updates, 2011
Sigma-Tau S.p.A., Subsidiaries
Sigma-Tau S.p.A., Deals Summary, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary by Region, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary, 2004 to YTD 2011
LIST OF FIGURES
Sigma-Tau S.p.A. – Pipeline by Therapy Area and Indication, 2011
Sigma-Tau S.p.A. – Pipeline by Stage of Development, 2011
Sigma-Tau S.p.A. – Monotherapy Products in Pipeline, 2011
Sigma-Tau S.p.A. – Combination Treatment Modalities in Pipeline, 2011
Sigma-Tau S.p.A. – Pipeline By Therapeutic Class, 2011
Sigma-Tau S.p.A. - Pipeline By Target, 2011
Sigma-Tau S.p.A. – Pipeline By Route of Administration, 2011
Sigma-Tau S.p.A. – Pipeline By Molecule Type, 2011
Table of Content
List of Tables
List of Figures
Sigma-Tau S.p.A. Snapshot
Sigma-Tau S.p.A. Overview
Key Information
Key Facts
Sigma-Tau S.p.A. – Research and Development Overview
Key Therapeutic Areas
Sigma-Tau S.p.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Sigma-Tau S.p.A. – Pipeline Products Glance
Sigma-Tau S.p.A. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Sigma-Tau S.p.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sigma-Tau S.p.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Sigma-Tau S.p.A. – Drug Profiles
Chenorm
Product Description
Mechanism of Action
R&D Progress
Cystoran
Product Description
Mechanism of Action
R&D Progress
Nuartez
Product Description
Mechanism of Action
R&D Progress
Acetyl-L-Carnitine
Product Description
Mechanism of Action
R&D Progress
Defibrotide
Product Description
Mechanism of Action
R&D Progress
Statins/Omega-3 PUFA
Product Description
Mechanism of Action
R&D Progress
Acetyl-L-Carnitine
Product Description
Mechanism of Action
R&D Progress
Dacarbazine + Interferon Apha + Thymosin-Alpha-1
Product Description
Mechanism of Action
R&D Progress
Dacarbazine + Thymosin-Alpha-1
Product Description
Mechanism of Action
R&D Progress
Gimatecan
Product Description
Mechanism of Action
R&D Progress
IART
Product Description
Mechanism of Action
R&D Progress
Rostafuroxin
Product Description
Mechanism of Action
R&D Progress
Teglicar
Product Description
Mechanism of Action
R&D Progress
Adarotene
Product Description
Mechanism of Action
R&D Progress
Namitecan
Product Description
Mechanism of Action
R&D Progress
ST1535
Product Description
Mechanism of Action
R&D Progress
STP-206
Product Description
Mechanism of Action
R&D Progress
DN30
Product Description
Mechanism of Action
R&D Progress
PTX3
Product Description
Mechanism of Action
R&D Progress
SST0001
Product Description
Mechanism of Action
R&D Progress
ST1936
Product Description
Mechanism of Action
R&D Progress
HSP90 inhibitors
Product Description
Mechanism of Action
R&D Progress
Sigma-Tau S.p.A. – Pipeline Analysis
Sigma-Tau S.p.A. – Pipeline Products by Therapeutic Class
Sigma-Tau S.p.A. - Pipeline Products By Target
Sigma-Tau S.p.A. – Pipeline Products by Route of Administration
Sigma-Tau S.p.A. – Pipeline Products by Molecule Type
Sigma-Tau S.p.A. – Recent Pipeline Updates
Sigma-Tau S.p.A. – Company Statement
Sigma-Tau S.p.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Sigma-Tau S.p.A., Deals Volume Summary, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary By Region, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary, 2004 to YTD 2011
Sigma-Tau S.p.A. Detailed Deal Summary
Equity Offering
RegeneRx Biopharmaceuticals Completes Private Placement Of $1 Million
RegeneRx Completes Private Placement Of $9.55 Million
Endotis Enters Into Manufacturing And Co-Development Agreement With Tecnogen
Anesiva Expands Its Agreement With Sigma-Tau
Anesiva Entered Into Agreement With Sigma-Tau
Recordati Signs Co-Marketing Agreement With Sigma-Tau
BurnsAdler Pharmaceuticals Enters Into Co-Promotion Agreement With Sigma-Tau
Licensing Agreements
Pfizer Enters Into Licensing Agreement With Sigma-Tau
Debiopharm Enters Into Licensing Agreement with Sigma-Tau
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Sigma-Tau S.p.A. – Pipeline by Therapy Area and Indication, 2011
Sigma-Tau S.p.A. – Pipeline by Stage of Development, 2011
Sigma-Tau S.p.A. – Monotherapy Products in Pipeline, 2011
Sigma-Tau S.p.A. – Combination Treatment Modalities in Pipeline, 2011
Sigma-Tau S.p.A. – Filed, 2011
Sigma-Tau S.p.A. – Phase III, 2011
Sigma-Tau S.p.A. - Phase II, 2011
Sigma-Tau S.p.A. - Phase I, 2011
Sigma-Tau S.p.A. - Pipeline By Therapeutic Class, 2011
Sigma-Tau S.p.A. - Pipeline By Target, 2011
Sigma-Tau S.p.A. – Pipeline By Route of Administration, 2011
Sigma-Tau S.p.A. – Pipeline By Molecule Type, 2011
Sigma-Tau S.p.A. – Recent Pipeline Updates, 2011
Sigma-Tau S.p.A., Subsidiaries
Sigma-Tau S.p.A., Deals Summary, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary by Region, 2004 to YTD 2011
Sigma-Tau S.p.A., Deals Summary, 2004 to YTD 2011
LIST OF FIGURES
Sigma-Tau S.p.A. – Pipeline by Therapy Area and Indication, 2011
Sigma-Tau S.p.A. – Pipeline by Stage of Development, 2011
Sigma-Tau S.p.A. – Monotherapy Products in Pipeline, 2011
Sigma-Tau S.p.A. – Combination Treatment Modalities in Pipeline, 2011
Sigma-Tau S.p.A. – Pipeline By Therapeutic Class, 2011
Sigma-Tau S.p.A. - Pipeline By Target, 2011
Sigma-Tau S.p.A. – Pipeline By Route of Administration, 2011
Sigma-Tau S.p.A. – Pipeline By Molecule Type, 2011
